An uncommon association of antiphospholipid syndrome, selective IgA deficiency and resistant-to-treatment relapsing polychondritis: efficacy of infliximab

Autoimmune complications in the context of primary immunodeficiency diseases represent a well-known phenomenon, and this is widely recognized also for Selective Immunoglobulin A deficiency (IgAD), the most common primary antibody deficiency (PAD). Relapsing polychondritis (RP) is a rare immune-media...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of biological regulators and homeostatic agents Vol. 26; no. 4; p. 785
Main Authors:	Firinu, D, Frau, A, Pisanu, M, Lorai, M M, Meleddu, R, Musu, F, Manconi, P E, Del Giacco, S R
Format:	Journal Article
Language:	English
Published:	Italy 01-10-2012
Subjects:	Antibodies, Monoclonal - therapeutic use Antiphospholipid Syndrome - complications Female Humans IgA Deficiency - complications Infliximab Middle Aged Polychondritis, Relapsing - drug therapy Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Autoimmune complications in the context of primary immunodeficiency diseases represent a well-known phenomenon, and this is widely recognized also for Selective Immunoglobulin A deficiency (IgAD), the most common primary antibody deficiency (PAD). Relapsing polychondritis (RP) is a rare immune-mediated, difficult to treat, disorder in which the cartilaginous tissues are the target for inflammation and damage. Ocular inflammatory manifestations in RP are frequent and often sight-threatening. Antiphospholipid syndrome (APS) is an acquired prothrombotic state related to circulating autoantibodies against phospholipids and/or their cofactors. Rare reports of APS associated to RP, PAD and APS or PAD and RP are available.
ISSN:	0393-974X